Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platelet Inhibition Clear all
Not listed Not applicable Interventional

The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A

NCT00004564
View directory record Official record
Conditions
Hypercholesterolemia, Thrombosis
Interventions
Clopidogrel, Atorvastatin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition in Patients With Systolic Heart Failure

NCT01765400
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Action of Acetaminophen

NCT00646906
View directory record Official record
Conditions
Myocardial Infarction, Arthritis
Interventions
Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d, Acetaminophen 4000 mg/d, Ibuprofen 800 mg/d
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 4 Interventional Results available

The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)

NCT02683707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine, Midazolam
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jul 23, 2026, 11:00 PM EDT
Withdrawn Phase 2 Interventional

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

NCT05509582
View directory record Official record
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 11:00 PM EDT
Active, not recruiting Phase 2 Interventional

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304
View directory record Official record
Conditions
Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
Interventions
Imatinib, Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 23, 2026, 11:00 PM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 2 Interventional Results available

Maintenance of Platelet Inhibition With Cangrelor

NCT00767507
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
cangrelor, Placebo
Drug · Other
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 1 Interventional

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

NCT02129101
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Polycythemia Vera, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sonidegib
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 2 Interventional Results available

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

NCT02298933
View directory record Official record
Conditions
Thrombocytopenia, Alloimmune Platelet Refractoriness
Interventions
Eculizumab
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 4 Interventional Results available

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

NCT03437044
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

NCT01094483
View directory record Official record
Conditions
Platelet Inhibition
Interventions
PN400, ASA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Jul 23, 2026, 11:00 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

NCT00263211
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Plavix, Aspirin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Jul 23, 2026, 11:00 PM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 11:00 PM EDT
Completed Phase 4 Interventional

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 11:00 PM EDT